COHORH STUDY A research paper on BMJ. What is cohort study? Investigates from exposure to outcome, in a group of patients without, or with appropriate.

Slides:



Advertisements
Similar presentations
Cardiovascular Risk Assessment
Advertisements

Agency for Healthcare Research and Quality (AHRQ)
How would you explain the smoking paradox. Smokers fair better after an infarction in hospital than non-smokers. This apparently disagrees with the view.
Carol Coupland Paula Dhiman Tony Arthur Richard Morriss Julia Hippisley-Cox University of Nottingham Garry Barton University of East Anglia Antidepressant.
Simulation of “forwards-backwards” multiple imputation technique in a longitudinal, clinical dataset Catherine Welch 1, Irene Petersen 1, James Carpenter.
Study Designs in Epidemiologic
Case-Control Studies (Retrospective Studies). What is a cohort?
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2010.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Is low-dose Aspirin use associated with a reduced risk of colorectal cancer ? a QResearch primary care database analysis Prof Richard Logan, Dr Yana Vinogradova,
Advances and Controversies in Cardiovascular Risk Prediction Peter Brindle General Practitioner R&D lead Bristol, N.Somerset and S.Glouc PCTs Promises,
UKPDS Paper 36 Slides © University of Oxford Diabetes Trials Unit UKPDS slides are copyright and remain the property of the University of Oxford Diabetes.
Journal Club Alcohol and Health: Current Evidence July–August 2004.
Cohort Studies.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2010.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May-June 2008.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Manish Chaudhary BPH, MPH
Predictors of 5-year mortality of 1,323 patients newly diagnosed with clinical type 2 diabetes in general practice With special emphasis on self-rated.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Diabetes incidence and long-term exposure to air pollution: a cohort study Zorana Jovanovic Andersen ISEE.
Dr. Abdulaziz BinSaeed & Dr. Hayfaa A. Wahabi Department of Family & Community medicine  Case-Control Studies.
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.
By Judith Graham heart-attacks/ The Deadly Threat of Silent Heart Attacks.
Lecture 6 Objective 16. Describe the elements of design of observational studies: (current) cohort studies (longitudinal studies). Discuss the advantages.
10 Points to Remember on the Assessment of Cardiovascular RiskAssessment of Cardiovascular Risk Summary Prepared by Melvyn Rubenfire, MD.
Combination Therapy for Hypertension Summary and Comment by Harlan M. Krumholz, MD, SM Published in Journal Watch Cardiology December 3, 2008Journal Watch.
Risk of colorectal cancer in patients taking statins and NSAIDS Dr Yana Vinogradova, Prof Julia Hippisley-Cox, Dr Carol Coupland and Prof Richard Logan.
Predicting risk of cardiovascular disease and the cost-effectiveness of interventions in Thailand Stephen Lim On Behalf of the Setting Priorities using.
10 Points to Remember on An Effective Approach to High Blood Pressure ControlAn Effective Approach to High Blood Pressure Control Summary Prepared by Debabrata.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Risk of malignancy in patients with mental health problems Julia Hippisley-Cox Yana Vinogradova Carol Coupland Chris Parker SAPC, Keele July 2006.
Exposure to cyclo-oxygenase-2 inhibitors and risk of cancer: nested case-control studies IAE world Congress Epidemiology 2011 Edinburgh Yana Vinogradova,
1 Ch 11 Estimating Risk: Is There an Association? Table 11-1 A hypothetical investigation of a foodborne disease outbreak The suspect foods were identified.
Study Designs for Clinical and Epidemiological Research Carla J. Alvarado, MS, CIC University of Wisconsin-Madison (608)
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Section III. Assessment of Overall Cardiovascular Risk in Hypertensive Patients 2015 Canadian Hypertension Education Program Recommendations.
A Claims Database Approach to Evaluating Cardiovascular Safety of ADHD Medications A. J. Allen, M.D., Ph.D. Child Psychiatrist, Pharmacologist Global Medical.
Hippisley-Cox J, Coupland C. Heart 2010;96:
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
PUTTING PREVENTION FIRST Vascular Checks/ NHS Health Checks.
NHS Health Check programme An opportunity to engage 15 million people to live well for longer Louise Cleaver National Programme Support Manager.
Kelsey Vonderheide, PA1.  Heart Failure—a large number of conditions affecting the structure and function of the heart that make it difficult for the.
Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Dose Aspirin for Primary Prevention of Cardiovascular.
CHEST 2014; 145(4): 호흡기내과 R3 박세정. Cigarette smoking ㅡ the most important risk factor for COPD in the US. low value of FEV 1 : an independent predictor.
1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
Presented by Slyter Nutrition Consulting Services.
From: Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study Ann Intern Med. 2015;163(5):
Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S.
Nephrology Journal Club The SPRINT Trial Parker Gregg
Alcohol, Other Drugs, and Health: Current Evidence July–August 2017
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
The SPRINT Research Group
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
HOPE: Heart Outcomes Prevention Evaluation study
Copyright © 2007 American Medical Association. All rights reserved.
Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations Cardiology 2015;132: DOI: / Fig. 1. Semilogarithmic.
Some Epidemiological Studies
Presenter: Wen-Ching Lan Date: 2018/08/01
Determinants of new onset diabetes among hypertensive patients randomised in the ASCOT-BPLA Trial Dr Ajay K Gupta International Centre for Circulatory.
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
A: Kaplan-Meier estimate of time to first LLA
Presenter: Wen-Ching Lan Date: 2018/10/17
Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.
ASCORE : An up-to-date cardiovascular risk score for hypertensive patients reflecting. contemporary clinical practices developed. using the ASCOT trial.
The following slides highlight a report by Dr
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Baseline Characteristics of the Subjects*
Presentation transcript:

COHORH STUDY A research paper on BMJ

What is cohort study? Investigates from exposure to outcome, in a group of patients without, or with appropriate control DATA; study in which subjects who presently have a certain condition and/or receive a particular treatment are followed over time and compared with another group who are not affected by the condition/have not this treatment

Experimental cohort study Experimental c.s. (syn. Randomized controlled clinical trial) cohorts of patients are prospectively and randomly allocated to treatment or control and effects (or adverse effects, AE) are monitored. Advantages: resistance to BIAS, great definitive power ; Disadvantages: time consuming, expensive, brief study length identifies only short terms adverse effects, size of study normally not large enough to permit identification of rare AEs

Observational cohort study Observational c.s. relies on the follow-up of patients and controls; patients are non-randomly assigned a treatment, a comparable group (control) is selected and assigned to either no treatment or another treatment; both groups are then followed prospectively to determine the outcome. Advantages: less expensive than experimental c.s., identifies new hazards even when they occur with a long latency, can estimate the risk Disadvantages: appropriate control group may be difficult to define, follow-up is often incomplete, bias may be introduced by choice of patients for different treatment according to the characteristics of the individual drugs

Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study Julia Hippisley-Cox; Carol Coupland; Yana Vinogradova BMJ 2007 Julia Hippisley-Cox; Carol Coupland; Yana Vinogradova BMJ 2007

Introduction CVD is the leading cause of premature death and a major cause of disability in the UK. Asymptomatic patients thought to be at high risk of cardiovascular disease need to be identified so they can be offered advice about lifestyle changes, such as smoking cessation, physical activity, and diet, about treatment to lower blood pressure and modify cholesterol levels, and about use of aspirin when appropriate. Framingham risk scores: developed during the peak incidence of cardiovascular disease in America. and over- estimate risk. Any systematic overestimation of risk results in an excessive number of people being identified for treatment. Scotland ASSIGN scores: different baseline.

Practices and cohorts We include all the contributing practices in the UK once they using their EMIS system for a year. We randomly allocated two thirds of eligible practices to the derivation dataset, saving the remaining third for the validation dataset. The derivation dataset was used to derive a new risk equation for estimating cardiovascular risk, validated using the validation dataset. Cohorts: We identified an open cohort of patients aged at the date of study entry, drawn from patients registered with eligible practices from 1 January 1995 to 1 April We excluded those with a diagnosis of cardiovascular disease or diabetes before their entry date. We also excluded temporary residents and patients with interrupted periods of registration with the practice. We also excluded 4% of patients who did not have a valid postcode related Townsend score. In addition we only include patients in the analysis once they had a minimum of one year complete data in their medical record.

Inclusion criteria and Exclusion criteria Inclusion criteria included all the contributing practices in the UK once they using their EMIS system for a year from 1 January 1995 to 1 April 2007 patients aged a minimum of one year complete data in their medical record. Exclusion criteria Diagnosis of cardiovascular disease or diabetes before their entry Temporary residents and patients with interrupted periods of registration with the practice Patients did not have a valid postcode related to Townsend scores

Cardiovascular disease risk factors Age (in single years) and Sex (men or women) Smoking (current smoker, non-smoker-including former smoker) Systolic blood pressure(continuous) Ratio of total serum cholesterol to high density lipoprotein level (continuous) Left ventricular hypertrophy recorded in clinical records Y/N Family history of cardiovascular disease in a first degree relative aged less than 60 Townsend deprivation score(a good area measure of material deprivation based on four variables) Current prescription of at least one antihypertensive()thiazide, β blocker, calcium channel blocker, or angiotensin converting enzyme inhibitor) BMI

Two cohorts In the validation dataset eligible patients were aged and of these 50.3% were women. 160 practices (1/3) In derivation cohort 1,283,174 patients were aged and were free of cardiovascular disease and diabetes at baseline. 318 practices (2/3) We randomly allocated 2/3 of 478 eligible practices to the derivation database, saving the remaining 1/3 for the validation database.

Entry date and censor date Entry date: For each patient we determined an entry date to the cohort analysis, which was the latest of the following dates: 35th birthday, date of registration with the practice, date on which the practice computer system was installed, and the beginning of the study period (1 January 1995). Censor date: the earliest date of the dates on which they developed the outcome of interest, the study period ended (1 April 2007), date of death, date of deregistration with the practice, or date of last upload of computerized data.

Cardiovascular disease outcomes The primary outcome was the first recorded diagnosis of cardiovascular disease on the general practice’s clinical computer system either before or at death occurring between 1 January 1995 and 1 April 2007 Cardiovascular disease: myocardial infarction, coronary heart disease, stroke, and transient ischaemic attack.

Baseline characteristics Derivation cohort: –8.4% of men and 12.4% of women were receiving treatment for blood pressure. –0.4% had a recorded diagnosis of left ventricular hypertrophy –9.1% of men and 12.1% of women had a family history of premature coronary heart disease in a first degree relative age less than 60.

Computer record incidence of cardiovascular disease per 1000 year person

Baseline clinical characters

Comparison with health survey for England

Adjusted hazard ratio with 95% CI

Model derivation and development  Cox proportional hazards model was used in the derivation dataset to estimate the coefficients associated with each potential risk facto.  Bayes information criterion was used to compared models.  We checked the assumptions of the proportional hazards model for each variable and tested for any non-linear relation between continuous Independent variables and the outcome.  We used fractional polynomials to model non-linear risk relations with continuous variables when appropriate